Safety and Tolerability of CTH120, First-in-human Phase I Study Encompassing Three Parts: Single and Multiple Ascending Doses and Potential Food Interaction
Latest Information Update: 12 Jul 2024
At a glance
- Drugs CTH 120 (Primary)
- Indications Fragile X syndrome
- Focus Adverse reactions; First in man; Pharmacokinetics
- Acronyms FIH-CTH120
- Sponsors Connecta Therapeutics
- 01 Jul 2024 Status changed from planning to recruiting.
- 06 Jun 2023 According to a Connecta Therapeutics media release, the Spanish Agency of Me=dicines and Medical Devices (AEMPS) has granted authorization to start this trial which will take place at Hospital del Mar Research Institute in Barcelona with Dr Rafael de la Torre and Dr Ana Aldea as principal investigator. Results from study are expected in the second quarter of 2024.
- 12 Aug 2021 New trial record